USFDA nods for Granules India\'s generic pain reliever

USFDA nods for Granules India's generic pain reliever

Press Trust of India  |  Hyderabad 

Thursday announced that the approved its Application (ANDA) for 650 mg Tablets, Extended Release, a generic version of 650mg tablets, Extended Release.

650 mg extended release tablets are used primarily for temporary management including relief, a press release from the city-based drug maker said.

"The addition of 650mg, extended release tablets to our OTC ( Over the Counter) portfolio leverages several components of our value proposition," Krishna Prasad Chigurupati, of Granules India said.

Granules India is the only supplier that is equipped with backward integration up to the Active Pharmaceutical Ingredient of this product, he added.

"With a capacity of over 24,000 tonnes per annum Acetaminophen and finished dosage capacity of more than 18 billion units/year, we are confident that we will ensure supply security to our customers which will support us to capture our target market share," Chigurupati said.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, April 18 2019. 15:30 IST